Open an account

aTyr Pharma

ATYR · NASDAQ

$0.1733+$0.0016 (+0.93%)TodayMarket closed ·
Prev close $0.1717

About ATYR

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. The company is headquartered in San Diego, California and currently employs 56 full-time employees. The company went IPO on 2015-05-07. The firm is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

Employees
56
Headquarters
San Diego, California
Listed
May 7, 2015
Sector
Health Care
Industry
Biotechnology
Website
atyrpharma.com

ATYR key statistics

Market cap
17.00M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
8.63M
Volume
1.32M
Open price
$0.1709
High today
$0.1778
Low today
$0.1653
52 Week high
$1.11
52 Week low
$0.165

aTyr Pharma (ATYR) at a glance

As of Oct 20, 2026, aTyr Pharma (ATYR) shares are priced at $0.1733, giving the company a market cap of 17.00M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.1653 and $0.1778. The current price is 4.8% above the day's low and 2.5% below its high.

Volume so far is 1.32M shares, below the average of 8.63M shares a day.

Over the past year aTyr Pharma has ranged from $0.165 to $1.11, and now sits 1% of the way up that range.

aTyr Pharma met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.11 per share against an estimate of -$0.1239.

The average analyst price target is $2.89, 1567.6% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 8 analystsAvg $2.89
Low
$1.01
Now
$0.1733
High
$7.35

ATYR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 18.5% on average.

  1. Q3 FY24: reported -$0.23 per share against an estimate of -$0.2244
  2. Q4 FY24: reported -$0.18 per share against an estimate of -$0.2305
  3. Q1 FY25: reported -$0.17 per share against an estimate of -$0.1938
  4. Q2 FY25: reported -$0.22 per share against an estimate of -$0.1881
  5. Q3 FY25: reported -$0.26 per share against an estimate of -$0.1873
  6. Q4 FY25: reported -$0.14 per share against an estimate of -$0.1874
  7. Q1 FY26: reported -$0.11 per share against an estimate of -$0.1403
  8. Q2 FY26: reported -$0.11 per share against an estimate of -$0.1239

ATYR news

  • Vandana Singh

    Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releasePRNewswire

    Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders

  • Press releasePRNewswire

    ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit

  • Press releaseGlobe Newswire

    Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

Similar companies

Companies in the same industry as aTyr Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.